Clinical Trial Details
| Trial ID: | L0240 |
| Source ID: | NCT00704678 |
| Associated Drug: | Sbr759 |
| Title: | Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis |
| Acronym: | SBR759 |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Chronic Kidney Disease |
| Interventions: | DRUG: SBR759|DRUG: Sevelamer HCl|DRUG: Sevelamer HCl|DRUG: Sevelamer HCl |
| Outcome Measures: | Primary: Responder rates achieving target serum phosphate levels., Week 12 | Secondary: Responder rates in target patients with serum calcium-phosphate levels., Week 12 |
| Sponsor/Collaborators: | Sponsor: Novartis Pharmaceuticals |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 203 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2008-08 |
| Completion Date: | |
| Results First Posted: | |
| Last Update Posted: | 2016-09-23 |
| Locations: | Novartis Investigative Site, Koriyama, Fukushima, Japan|Novartis Investigative Site, Midori, Gunma, Japan|Novartis Investigative Site, Hitachiomiya, Ibaraki, Japan|Novartis Investigative Site, Moriya, Ibaraki, Japan|Novartis Investigative Site, Sashima-gun, Ibaraki, Japan|Novartis Investigative Site, Takamatsu, Kagawa, Japan|Novartis Investigative Site, Tsu, Mie, Japan|Novartis Investigative Site, Okayama City, Okayama, Japan|Novartis Investigative Site, Sakai, Osaka, Japan|Novartis Investigative Site, Kasukabe, Saitama, Japan|Novartis Investigative Site, Nagano, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan |
| URL: | https://clinicaltrials.gov/show/NCT00704678 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|